0000719135 FALSE December 31 Q1 2023 0000719135 2023-01-01 2023-03-31 0000719135 2023-05-10 xbrli:shares 0000719135 2023-03-31 iso4217:USD 0000719135 2022-12-31 iso4217:USD xbrli:shares 0000719135 2022-01-01 2022-03-31 0000719135 us-gaap:CommonStockMember 2021-12-31 0000719135 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000719135 us-gaap:RetainedEarningsMember 2021-12-31 0000719135 us-gaap:NoncontrollingInterestMember 2021-12-31 0000719135 2021-12-31 0000719135 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000719135 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000719135 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000719135 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0000719135 us-gaap:CommonStockMember 2022-03-31 0000719135 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000719135 us-gaap:RetainedEarningsMember 2022-03-31 0000719135 us-gaap:NoncontrollingInterestMember 2022-03-31 0000719135 2022-03-31 0000719135 us-gaap:CommonStockMember 2022-12-31 0000719135 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000719135 us-gaap:RetainedEarningsMember 2022-12-31 0000719135 us-gaap:NoncontrollingInterestMember 2022-12-31 0000719135 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000719135 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000719135 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0000719135 us-gaap:CommonStockMember 2023-03-31 0000719135 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000719135 us-gaap:RetainedEarningsMember 2023-03-31 0000719135 us-gaap:NoncontrollingInterestMember 2023-03-31 0000719135 2018-01-01 2018-12-31 0000719135 2022-01-01 2022-12-31 0000719135 2023-02-17 0000719135 apyx:ShelfRegistrationMember 2022-11-22 2022-11-22 0000719135 apyx:AtTheMarketFacilityMember 2022-11-22 2022-11-22 0000719135 us-gaap:LineOfCreditMember apyx:CreditAgreementMember 2023-02-17 0000719135 us-gaap:LineOfCreditMember apyx:CreditAgreementMember us-gaap:SecuredDebtMember 2023-02-17 0000719135 us-gaap:LineOfCreditMember apyx:CreditAgreementMember apyx:DebtInstrumentCovenantTrancheOneMember us-gaap:SecuredDebtMember 2023-02-17 0000719135 us-gaap:LineOfCreditMember apyx:CreditAgreementMember us-gaap:SecuredDebtMember apyx:DebtInstrumentCovenantTrancheTwoMember 2023-02-17 0000719135 us-gaap:LineOfCreditMember apyx:CreditAgreementMember us-gaap:SecuredDebtMember apyx:DebtInstrumentCovenantTrancheThreeMember 2023-02-17 0000719135 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember apyx:CreditAgreementMember 2023-02-17 0000719135 2023-03-14 2023-03-14 0000719135 2023-01-01 2023-01-31 0000719135 2023-01-09 2023-01-09 xbrli:pure 0000719135 us-gaap:LandMember 2023-03-31 0000719135 us-gaap:LandMember 2022-12-31 0000719135 us-gaap:BuildingAndBuildingImprovementsMember 2023-03-31 0000719135 us-gaap:BuildingAndBuildingImprovementsMember 2022-12-31 0000719135 us-gaap:MachineryAndEquipmentMember 2023-03-31 0000719135 us-gaap:MachineryAndEquipmentMember 2022-12-31 0000719135 us-gaap:FurnitureAndFixturesMember 2023-03-31 0000719135 us-gaap:FurnitureAndFixturesMember 2022-12-31 0000719135 apyx:ComputerEquipmentAndSoftwareMember 2023-03-31 0000719135 apyx:ComputerEquipmentAndSoftwareMember 2022-12-31 0000719135 us-gaap:LeaseholdImprovementsMember 2023-03-31 0000719135 us-gaap:LeaseholdImprovementsMember 2022-12-31 0000719135 apyx:MoldsMember 2023-03-31 0000719135 apyx:MoldsMember 2022-12-31 0000719135 us-gaap:SubsequentEventMember 2023-05-08 2023-05-08 0000719135 apyx:AdjustedTermSecuredOvernightFinancingRateSOFRMember us-gaap:LineOfCreditMember apyx:CreditAgreementMember us-gaap:SecuredDebtMember 2023-02-17 2023-02-17 0000719135 us-gaap:LineOfCreditMember apyx:CreditAgreementMember us-gaap:SecuredDebtMember 2023-02-17 2023-02-17 apyx:monthlyPayment 0000719135 us-gaap:LineOfCreditMember apyx:CreditAgreementMember us-gaap:SecuredDebtMember apyx:DebtInstrumentPrepaymentPeriodOneMember 2023-02-17 2023-02-17 0000719135 apyx:DebtInstrumentPrepaymentPeriodTwoMember us-gaap:LineOfCreditMember apyx:CreditAgreementMember us-gaap:SecuredDebtMember 2023-02-17 2023-02-17 0000719135 us-gaap:LineOfCreditMember apyx:CreditAgreementMember us-gaap:SecuredDebtMember apyx:DebtInstrumentPrepaymentPeriodThreeMember 2023-02-17 2023-02-17 0000719135 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember apyx:CreditAgreementMember apyx:DebtInstrumentTerminationPeriodOneMember 2023-02-17 0000719135 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember apyx:CreditAgreementMember apyx:DebtInstrumentTerminationPeriodOneMember 2023-02-17 2023-02-17 0000719135 apyx:AdjustedTermSecuredOvernightFinancingRateSOFRMember us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember apyx:CreditAgreementMember 2023-02-17 2023-02-17 0000719135 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember apyx:CreditAgreementMember 2023-02-17 2023-02-17 0000719135 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember apyx:DebtInstrumentTerminationPeriodTwoMember apyx:CreditAgreementMember 2023-02-17 2023-02-17 0000719135 apyx:DebtInstrumentTerminationPeriodThreeMember us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember apyx:CreditAgreementMember 2023-02-17 2023-02-17 0000719135 2023-02-17 2023-02-17 0000719135 us-gaap:LineOfCreditMember apyx:CreditAgreementMember 2023-02-17 2023-02-17 0000719135 us-gaap:LineOfCreditMember apyx:CreditAgreementMember us-gaap:SecuredDebtMember 2023-01-01 2023-03-31 0000719135 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember apyx:CreditAgreementMember 2023-01-01 2023-03-31 0000719135 us-gaap:LineOfCreditMember us-gaap:LineOfCreditMember 2023-03-31 0000719135 apyx:ChineseSupplierMember 2019-12-31 0000719135 2019-12-31 0000719135 2021-01-01 2021-12-31 0000719135 2020-01-01 2020-12-31 0000719135 us-gaap:CorporateJointVentureMember 2022-12-31 0000719135 us-gaap:CorporateJointVentureMember 2021-12-31 0000719135 us-gaap:CorporateJointVentureMember 2023-01-01 2023-03-31 0000719135 us-gaap:CorporateJointVentureMember 2022-01-01 2022-03-31 0000719135 us-gaap:CorporateJointVentureMember 2023-03-31 0000719135 us-gaap:CorporateJointVentureMember 2022-03-31 0000719135 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0000719135 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0000719135 us-gaap:WarrantMember 2023-01-01 2023-03-31 0000719135 us-gaap:WarrantMember 2022-01-01 2022-03-31 0000719135 srt:MinimumMember 2021-12-31 0000719135 srt:MaximumMember 2021-12-31 0000719135 srt:MinimumMember apyx:SuitAgainstGoodwinAndSimbMember 2022-12-31 0000719135 srt:MaximumMember apyx:SuitAgainstGoodwinAndSimbMember 2022-12-31 0000719135 apyx:SuitAgainstGoodwinAndSimbMember 2022-12-31 0000719135 apyx:SuitsFiledIn2022Member 2022-01-01 2022-12-31 apyx:lease 0000719135 apyx:SuitsFiledIn2022Member srt:MinimumMember 2023-03-31 0000719135 srt:MaximumMember apyx:SuitsFiledIn2022Member 2023-03-31 0000719135 apyx:SuitsFiledIn2022Member 2023-03-31 0000719135 us-gaap:CoVenturerMember 2023-01-01 2023-03-31 0000719135 us-gaap:CoVenturerMember 2022-01-01 2022-03-31 0000719135 us-gaap:CoVenturerMember 2023-03-31 0000719135 us-gaap:CoVenturerMember 2022-12-31 apyx:segment 0000719135 us-gaap:OperatingSegmentsMember apyx:AdvancedEnergyMember 2023-01-01 2023-03-31 0000719135 apyx:OEMMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-03-31 0000719135 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-03-31 0000719135 us-gaap:OperatingSegmentsMember apyx:AdvancedEnergyMember 2022-01-01 2022-03-31 0000719135 apyx:OEMMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-03-31 0000719135 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-03-31 0000719135 country:US 2023-01-01 2023-03-31 0000719135 country:US 2022-01-01 2022-03-31 0000719135 us-gaap:NonUsMember 2023-01-01 2023-03-31 0000719135 us-gaap:NonUsMember 2022-01-01 2022-03-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q

|  | ☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|  |  | For the quarterly period ended | March 31, 2023
|  |  | or
|  | ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|  |  | For the transition period from _____ to _____
|  |  | Commission File Number: | 0-12183

APYX MEDICAL CORPORATION
(Exact name of registrant as specified in its charter)

Delaware |  | 11-2644611
(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)

5115 Ulmerton Road, Clearwater, FL 33760
(Address of principal executive offices, zip code)
(727) 384-2323
(Registrant’s telephone number)
Securities Registered Pursuant to Section 12 (b) of the Act:

Title of each class | Trading symbol(s) | Name of each exchange on which registered
Common Stock | APYX | Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes: ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes: ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer | ☐ |  | Accelerated filer | ☐
Non-accelerated filer | ☒ |  | Smaller reporting company | ☒
|  |  | Emerging growth company | ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes: ☐ No ☒
A s of May 10, 2023, 34,597,822 shares of the registrant’s $0.001 par value common stock were outstanding.

Table of Contents
APYX MEDICAL CORPORATION
INDEX TO QUARTERLY REPORT ON FORM 10-Q
For the quarterly period ended March 31, 2023

|  |  |  | Page
Part I. |  | Financial Information |  | 2
Item 1. |  | Condensed Consolidated Financial Statements (Unaudited) |  | 2
|  | Condensed Consolidated Balance Sheets at March 31, 2023 and December 31, 2022 |  | 2
|  | Condensed Consolidated Statements of Operations for the three months ended March 31, 2023 and 2022 |  | 3
|  | Condensed Consolidated Statements of Changes in Equity for the three months ended March 31, 2023 and 2022 |  | 4
|  | Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and 2022 |  | 5
|  | Notes to Condensed Consolidated Financial Statements |  | 6
Item 2. |  | Management’s Discussion and Analysis of Financial Condition and Results of Operations |  | 20
Item 3. |  | Quantitative and Qualitative Disclosures about Market Risk |  | 29
Item 4. |  | Controls and Procedures |  | 30
Part II. |  | Other Information |  | 31
Item 1. |  | Legal Proceedings |  | 31
Item 1A. |  | Risk Factors |  | 32
Item 2. |  | Unregistered Sales of Equity Securities and Use of Proceeds |  | 33
Item 3. |  | Defaults Upon Senior Securities |  | 33
Item 4. |  | Mine Safety Disclosures |  | 33
Item 5. |  | Other Information |  | 33
Item 6. |  | Exhibits |  | 34
|  | Signatures |  | 35

1

Table of Contents
PART I. Financial Information
ITEM 1. Condensed Consolidated Financial Statements
APYX MEDICAL CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)

| March 31, 2023 (Unaudited) |  | December 31, 2022
ASSETS |  |  |
Current assets: |  |  |
Cash and cash equivalents | $ | 16,255 |  |  | $ | 10,192 |
Trade accounts receivable, net of allowance of $359 and $668 | 9,966 |  |  | 10,602 |
Income tax receivables | 7,752 |  |  | 7,545 |
Other receivables | 417 |  |  | 99 |
Inventories, net of provision for obsolescence of $428 and $457 | 10,946 |  |  | 11,797 |
Assets held for sale | 4,569 |  |  | — |
Prepaid expenses and other current assets | 2,779 |  |  | 2,737 |
Total current assets | 52,684 |  |  | 42,972 |
Property and equipment, net | 2,109 |  |  | 6,761 |
Operating lease right-of-use assets | 646 |  |  | 710 |
Finance lease right-of-use assets | 106 |  |  | 115 |
Other assets | 1,239 |  |  | 1,217 |
Total assets | $ | 56,784 |  |  | $ | 51,775 |
LIABILITIES AND EQUITY |  |  |
Current liabilities: |  |  |
Accounts payable | $ | 1,905 |  |  | $ | 2,669 |
Accrued expenses and other current liabilities | 7,626 |  |  | 8,928 |
Current portion of operating lease liabilities | 184 |  |  | 216 |
Current portion of finance lease liabilities | 33 |  |  | 37 |
Term loan, net | 8,778 |  |  | — |
Total current liabilities | 18,526 |  |  | 11,850 |
Long-term operating lease liabilities | 448 |  |  | 470 |
Long-term finance lease liabilities | 68 |  |  | 73 |
Long-term contract liabilities | 1,343 |  |  | 1,408 |
Other liabilities | 185 |  |  | 181 |
Total liabilities | 20,570 |  |  | 13,982 |
EQUITY |  |  |
Preferred Stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of March 31, 2023 and December 31, 2022 | — |  |  | — |
Common stock, $0.001 par value; 75,000,000 shares authorized; 34,597,822 issued and outstanding as of March 31, 2023 and December 31, 2022 | 35 |  |  | 35 |
Additional paid-in capital | 75,235 |  |  | 73,282 |
Accumulated deficit | (39,218) |  |  | (35,735) |
Total stockholders' equity | 36,052 |  | 37,582
Non-controlling interest | 162 |  |  | 211 |
Total equity | 36,214 |  |  | 37,793 |
Total liabilities and equity | $ | 56,784 |  |  | $ | 51,775 |

The accompanying notes are an integral part of the condensed consolidated financial statements.
2

Table of Contents
APYX MEDICAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except per share data)

| Three Months Ended March 31, |  |
| 2023 |  | 2022 |  |  |  |  |  |
Sales | $ | 12,142 |  |  | $ | 12,493 |  |  |  |  |  |  |
Cost of sales | 4,569 |  |  | 4,274 |  |  |  |  |  |  |
Gross profit | 7,573 |  |  | 8,219 |  |  |  |  |  |  |
Other costs and expenses: |  |  |  |  |  |  |  |  |
Research and development | 1,121 |  |  | 1,158 |  |  |  |  |  |  |
Professional services | 1,740 |  |  | 2,286 |  |  |  |  |  |  |
Salaries and related costs | 5,068 |  |  | 5,181 |  |  |  |  |  |  |
Selling, general and administrative | 5,255 |  |  | 5,465 |  |  |  |  |  |  |
Total other costs and expenses | 13,184 |  |  | 14,090 |  |  |  |  |  |  |
Loss from operations | (5,611) |  |  | (5,871) |  |  |  |  |  |  |
Interest income | 51 |  |  | 2 |  |  |  |  |  |  |
Interest expense | (234) |  |  | (8) |  |  |  |  |  |  |
Other loss, net | (5) |  |  | (21) |  |  |  |  |  |  |
Total other loss, net | (188) |  |  | (27) |  |  |  |  |  |  |
Loss before income taxes | (5,799) |  |  | (5,898) |  |  |  |  |  |  |
Income tax (benefit) expense | (2,267) |  |  | 70 |  |  |  |  |  |  |
Net loss | (3,532) |  |  | (5,968) |  |  |  |  |  |  |
Net loss attributable to non-controlling interest | (49) |  | (23) |  |  |  |  |  |  |
Net loss attributable to stockholders | $ | (3,483) |  |  | $ | (5,945) |  |  |  |  |  |  |
Loss per share: |  |  |  |  |  |  |  |  |
Basic and diluted | $ | (0.10) |  |  | $ | (0.17) |  |  |  |  |  |  |

The accompanying notes are an integral part of the condensed consolidated financial statements.
3

Table of Contents
APYX MEDICAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(Unaudited)
(In thousands)

Three Months Ended March 31, 2023 and 2022 |  |  |  |  |  |  |  |  |  |  |
| Common Stock |  | Additional Paid-In Capital |  | Accumulated Deficit |  | Non-controlling Interest |  | Total Equity
| Shares |  | Par Value |  |  |  |
Balance at December 31, 2021 | 34,410 |  |  | $ | 34 |  |  | $ | 66,221 |  |  | $ | (12,551) |  |  | $ | 305 |  |  | $ | 54,009 |
Shares issued on stock options exercises for cash | 24 |  |  | — |  |  | 152 |  |  | — |  |  | — |  | 152 |
Stock based compensation | — |  |  | — |  |  | 1,650 |  |  | — |  |  | — |  | 1,650 |
Shares issued on net settlement of stock options | 19 |  |  | — |  |  | — |  |  | — |  |  | — |  | — |
Net loss | — |  |  | — |  |  | — |  |  | (5,945) |  |  | (23) |  | (5,968) |
Balance at March 31, 2022 | 34,453 |  |  | $ | 34 |  |  | $ | 68,023 |  |  | $ | (18,496) |  |  | $ | 282 |  |  | $ | 49,843 |
Balance at December 31, 2022 | 34,598 |  |  | $ | 35 |  |  | $ | 73,282 |  |  | $ | (35,735) |  |  | $ | 211 |  |  | $ | 37,793 |
Stock based compensation | — |  |  | — |  |  | 1,367 |  |  | — |  |  | — |  | 1,367 |
Proceeds received from issuance of warrants | — |  |  | — |  |  | 586 |  |  | — |  |  | — |  | 586 |
Net loss | — |  |  | — |  |  | — |  |  | (3,483) |  |  | (49) |  | (3,532) |
Balance at March 31, 2023 | 34,598 |  |  | $ | 35 |  |  | $ | 75,235 |  |  | $ | (39,218) |  |  | $ | 162 |  |  | $ | 36,214 |

The accompanying notes are an integral part of the condensed consolidated financial statements.
4

Table of Contents
APYX MEDICAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)

| Three Months Ended March 31,
| 2023 |  | 2022 |  |
Cash flows from operating activities |  |  |  |  |
Net loss | $ | (3,532) |  |  | $ | (5,968) |  |  |
Adjustments to reconcile net loss to net cash used in operating activities: |  |  |  |  |
Depreciation and amortization | 203 |  |  | 225 |  |  |
Provision for inventory obsolescence | — |  |  | 85 |  |  |
Loss on disposal of property and equipment | — |  |  | 26 |  |  |
Stock based compensation | 1,367 |  |  | 1,650 |  |  |
Provision for allowance for doubtful accounts | (142) |  |  | 140 |  |  |
Non-cash interest expense | 67 |  |  | — |  |  |
Changes in operating assets and liabilities: |  |  |  |  |
Trade receivables | 837 |  |  | 475 |  |  |
Prepaid expenses and other assets | 858 |  |  | 649 |  |  |
Income tax receivables | (207) |  |  | — |  |  |
Inventories | 879 |  |  | (371) |  |  |
Accounts payable | (776) |  |  | (51) |  |  |
Accrued expenses and other liabilities | (1,435) |  |  | (1,378) |  |  |
Net cash used in operating activities | (1,881) |  |  | (4,518) |  |  |
Cash flows from investing activities |  |  |  |  |
Purchases of property and equipment | (110) |  |  | (279) |  |  |
Net cash used in investing activities | (110) |  |  | (279) |  |  |
Cash flows from financing activities |  |  |  |  |
Proceeds from stock option exercises | — |  |  | 152 |  |  |
Proceeds from term loan | 9,289 |  |  | — |  |  |
Payment of debt issuance costs | (1,754) |  |  | — |  |  |
Proceeds from issuance of warrants | 586 |  |  | — |  |  |
Repayment of finance lease liabilities | (9) |  |  | (54) |  |  |
Net cash provided by financing activities | 8,112 |  |  | 98 |  |  |
Effect of exchange rates on cash | (58) |  |  | 63 |  |  |
Net change in cash and cash equivalents | 6,063 |  |  | (4,636) |  |  |
Cash and cash equivalents, beginning of period | 10,192 |  |  | 30,870 |  |  |
Cash and cash equivalents, end of period | $ | 16,255 |  |  | $ | 26,234 |  |  |
Cash paid for: |  |  |  |  |
Interest | $ | 1 |  |  | $ | 8 |  |  |
Income taxes | 125 |  |  | — |  |  |

The accompanying notes are an integral part of the condensed consolidated financial statements.
5

Table of Contents
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 1. BASIS OF PRESENTATION
Apyx Medical Corporation (“Company”, “Apyx”, “it” and similar terms) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760.
The Company is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Technology products marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion® and J-Plasma® offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers.
As part of its plan to accelerate and fully fund the development of its advanced energy business, with a focus in the cosmetic surgery market, the Company sold its Core business in 2018 for gross proceeds of $97 million. These proceeds were used to launch broad marketing and sales initiatives which resulted in rapid sales growth through December 31, 2021 and into the first quarter of 2022. This planned growth in the business was accompanied by scaled operations, including procurement of components, expanded manufacturing capacity to turn those materials into saleable inventory, additional discretionary expenditures, including increased global participation at trade shows, additional employee trainings, user meetings, increased travel and entertainment expenses, more expansive research and development projects, and additional headcount to support those activities. Additionally, the Company had, and still has, some significant non-recurring discretionary expenditures associated with completing its multi-year marketing initiatives related to its dermal resurfacing and skin laxity clearances.
On March 14, 2022, the U.S. Food and Drug Administration (“FDA”) posted a Medical Device Safety Communication (“Safety Communication”). The FDA warned against the use of Renuvion/J-Plasma for procedures intended to improve the appearance of the skin through dermal resurfacing (a procedure on the skin to treat wrinkles) or skin contraction (a procedure under the skin that can be performed either alone or in combination with liposuction to achieve skin effects, such as “tightening”). At that time, the Renuvion/J-Plasma device system was FDA cleared for general use of cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures. The use of the device had not been determined to be safe or effective for any aesthetic skin procedures (procedures intended to improve the appearance of the skin). Following the Safety Communication, the Company experienced slowed demand for the adoption of its Helium Plasma Technology.
On May 26, 2022, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® Dermal Handpiece for certain dermal resurfacing procedures, specifically, for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick Skin Types I, II or III.
On June 2, 2022, the FDA updated the Safety Communication to inform consumers and healthcare providers about the new 510(k) clearance for the Renuvion® device system for certain dermal resurfacing procedures.
On July 18, 2022, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for use in subcutaneous dermatological and aesthetic procedures to improve the appearance of lax (loose) skin in the neck and submental (under the chin) region.
On July 21, 2022, the FDA updated the Safety Communication to inform consumers and healthcare providers about the clearance for the Renuvion® APR handpieces for use under the skin in certain procedures intended to improve the appearance of loose skin.
On February 27, 2023, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue.
On April 28, 2023, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.
On May 10, 2023, the FDA updated the Safety Communication to inform consumers and healthcare providers about the clearance for the Renuvion® APR handpiece for use under the skin in certain procedures intended to improve the appearance of the skin, including for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.
6

Table of Contents
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)
Management believes that the May 10, 2023 FDA update to the Safety Communication addresses the issues set forth in the original Safety Communication from March 14, 2022. While no assurances can be provided, management believes that receiving these additional clearances and the corresponding updates to the Safety Communication since March 14, 2022 should mitigate the financial effects of the Safety Communication in future periods.
The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.
Pursuant to the requirements of the Financial Accounting Standards Board’s Accounting Standards Codification (“ASC”) Topic 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for one year from the date these unaudited condensed consolidated financial statements are issued. This evaluation does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented or are not within control of the Company as of the date the unaudited condensed consolidated financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued.
While sales were continuing to grow into the first quarter of 2022 prior to the FDA Safety Communication, over the last few years, exclusive of the Company’s sale of the Core business segment to Symmetry Surgical during 2018, the Company has incurred recurring net losses and cash outflows from operations and the Company anticipates that losses will continue in the near term. During the year ended December 31, 2022, the Company incurred an operating loss of $23.6 million and used $20.3 million of cash in operations. During the three months ended March 31, 2023, the Company incurred an operating loss of $5.6 million and used $1.9 million of cash in operations. As of March 31, 2023, the Company had cash and cash equivalents of $16.3 million, of which the Company must maintain $10.0 million under its Credit Agreement. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements.
In an effort to alleviate these conditions, the Company pursued various funding solutions in order to improve liquidity.
On November 22, 2022, the Company filed a shelf registration statement providing it the ability to register securities in the aggregate amount up to $100 million. The shelf registration included an embedded ATM facility for up to $40 million. To date, the Company has not utilized this facility.
On February 17, 2023, the Company entered into a Credit, Security and Guaranty Agreement (the “Credit Agreement”) with MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time.
The Credit Agreement provides for an up to $35 million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provides for senior secured term loans of up to $25 million, comprised of (i) an initial tranche of $10 million, (ii) a second tranche of $5 million, and (iii) a third tranche of $10 million. The secured revolving facility provides for loans in an aggregate principal amount of up to $10 million, subject to a borrowing base equal to certain percentages of the Company’s eligible accounts receivable and inventory, as determined in accordance with the terms of the Credit Agreement.
For a more in depth description of the terms of the Credit Agreement, see Note 6.
On February 27, 2023, the Company’s Board of Directors approved a plan to sell and leaseback the Company’s real property located in Clearwater, FL. On March 14, 2023, the Company entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with VK Acquisitions VI, LLC (the “Purchaser”), for the sale of the Company’s facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the “Property”) for a purchase price
7

Table of Contents
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)
of $7,650,000. On May 8, 2023, the Company closed on the Purchase Agreement and concurrently executed a 10-year agreement to leaseback the underlying Property from the Purchaser.
For a more in depth description of the terms of the Purchase Agreement, see Note 4.
During January 2023, the Company was notified that the IRS examination process of our 2018, 2019 and 2020 tax returns was complete and that the Company’s tax refunds were approved for approximately $0.2 million more than the amount recorded in the Company’s Consolidated Balance Sheet at December 31, 2022. As of the date of this report, the Company is awaiting receipt of the tax refunds.
The Company also continues to re-assess its operating expenditures and cost structure to be commensurate with expected levels of revenue and management has the ability to reduce or delay expenditures to enhance and preserve liquidity. Management has already reduced some operating expenditures, including a reduction-in-force on January 9, 2023, that reduced the Company’s U.S. headcount by 14%.
Management believes that the actions already taken, and additional actions that it intends to take to manage operating expenditures, will enable the Company to meet its obligations and its debt covenants for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements. As a result, management believes its plans alleviate substantial doubt about the Company’s ability to continue as a going concern. These unaudited condensed consolidated financial statements do not include any adjustments relating to the carrying amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern.
NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS
In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments—Credit Losses (Topic 326). The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company adopted the new standard on January 1, 2023 and its impact was not material to the Company.
No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.
8

Table of Contents
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)
NOTE 3. INVENTORIES
Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours.
Inventories consisted of the following:

(In thousands) | March 31, 2023 |  | December 31, 2022
Raw materials | $ | 4,388 |  |  | $ | 4,979 |
Work in process | 2,331 |  |  | 2,160 |
Finished goods | 4,655 |  |  | 5,115 |
Gross inventories | 11,374 |  |  | 12,254 |
Less: provision for obsolescence | (428) |  |  | (457) |
Inventories, net | $ | 10,946 |  |  | $ | 11,797 |

NOTE 4. ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT

(In thousands) | March 31, 2023 (Unaudited) |  | December 31, 2022
Land | $ | — |  |  | $ | 1,600 |
Building and improvements | 16 |  |  | 4,426 |
Machinery and equipment | 2,472 |  |  | 2,613 |
Furniture and fixtures | 213 |  |  | 211 |
Computer equipment and software | 1,230 |  |  | 1,420 |
Leasehold improvements | 178 |  |  | 178 |
Molds | 847 |  |  | 847 |
Total property, plant and equipment | 4,956 |  |  | 11,295 |
Less: accumulated depreciation and amortization | (3,387) |  |  | (5,041) |
Property and equipment in service | 1,569 |  |  | 6,254 |
Construction in progress | 540 |  |  | 507 |
Property and equipment, net | $ | 2,109 |  |  | $ | 6,761 |
Assets held for sale | $ | 4,569 |  |  | $ | — |

In an effort to improve liquidity and the balance sheet condition of the Company, management has been exploring options to leverage the Company’s unencumbered real property. On February 27, 2023, the Company’s Board of Directors approved a plan to sell and leaseback the Company's real property located in Clearwater, FL.
On March 14, 2023, the Company entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with VK Acquisitions VI, LLC (the “Purchaser”), for the sale of the Company’s facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the “Property”) for a purchase price of $7,650,000.
9

Table of Contents
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)
In accordance with the requirements of ASC Topic 360, Property, Plant, and Equipment, the Company has determined that the real property to be sold meets the requirements to be presented as held for sale. Accordingly, the Company has presented the associated assets as held for sale in the accompanying unaudited condensed consolidated balance sheet and the table above at March 31, 2023.
In accordance with the terms of the Purchase Agreement, upon the closing of the sale of the Property, the Company will enter into a Single Tenant Industrial Building Lease (the “Lease”) with the Purchaser, pursuant to which the Property will be leased back to the Company. The Lease will have an initial term of ten (10) years commencing from the closing (the “Initial Term”), and a renewal term of five (5) years, exercisable at the Company’s option. The annual fixed rent will be $619,500 for the first year of the Initial Term, and will be subject to a 4% escalation every year thereafter through the Initial Term. Rent will be reset to the current market rate should the Company exercise the renewal option. The Lease provides for a 3% management fee on rent payments throughout the Initial Term and optional renewal term.
The Lease is a triple net lease, pursuant to which all costs, expenses, and obligations relating to the Property, including, repair and maintenance charges, utility charges, real estate taxes or other taxes that may be imposed that relate to the Property, shall be paid by the Company. In addition, the Lease contains other customary terms and provisions generally contained within leases of this type.
On May 8, 2023, the Company closed on the Purchase Agreement and concurrently executed a 10-year agreement to leaseback the underlying Property from the Purchaser. The Company received net cash proceeds of approximately $6,600,000, after withholding the security deposit equal to one years rent, taxes, first months rent, expenses, and fees. The Company anticipates that the net cash proceeds will be used to strengthen its balance sheet and provide working capital to its operations.
NOTE 5. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Accrued expenses and other current liabilities consisted of the following:

(in thousands) | March 31, 2023 |  | December 31, 2022
Accrued payroll | $ | 848 |  |  | $ | 563 |
Accrued bonuses | 570 |  |  | — |
Accrued commissions | 790 |  |  | 847 |
Accrued product warranties | 368 |  |  | 391 |
Accrued product liability claim insurance deductibles | 1,794 |  |  | 1,825 |
Accrued professional fees and legal related contingent liabilities | 924 |  |  | 901 |
Short-term contract liabilities | 1,053 |  |  | 853 |
Joint and several payroll liability | 345 |  |  | 345 |
Uncertain tax positions | — |  |  | 2,079 |
Sales tax payable | 211 |  |  | 245 |
Other accrued expenses and current liabilities | 723 |  |  | 879 |
Total accrued expenses and other current liabilities | $ | 7,626 |  |  | $ | 8,928 |

During April 2023, the Company was relieved of the remainder of its joint and several payroll liability due to the lapse of the statute of limitations on the liability.
NOTE 6. CREDIT AGREEMENT
On February 17, 2023, the Company entered into a Credit, Security and Guaranty Agreement (the “Credit Agreement”), by and among the Company (as borrower) and Apyx China Holding Corp., the Company’s wholly-owned subsidiary (as guarantor), and MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time (collectively “MidCap”).
10

Table of Contents
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)
The Credit Agreement provides for an up to $35 million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provides for senior secured term loans of up to $25 million, comprised of (i) an initial tranche of $10 million, (ii) a second tranche of $5 million, and (iii) a third tranche of $10 million. The secured revolving facility provides for loans in an aggregate principal amount of up to $10 million, subject to a borrowing base equal to percentages of eligible accounts receivable and inventory determined in accordance with the Credit Agreement. The Credit Agreement matures on February 1, 2028.
Term Loans
The initial tranche of $10 million was fully funded on February 17, 2023 less transaction costs. Subject to certain terms and conditions of the Credit Agreement, the second tranche would be available between June 30, 2023 and December 31, 2023 and the third tranche would be available between January 1, 2024 and September 30, 2024, respectively. The Company’s ability to access these additional tranches is conditioned upon, among other things, the achievement of certain minimum revenue targets.
Each term loan bears interest at a floating rate reset monthly based on an adjusted one month SOFR plus 0.1%, subject to a floor of 2.5%, plus 7.35% calculated on a 360 day basis (12.1% at March 31, 2023). Interest is payable monthly in arrears on the first day of each month.
The first twenty-four (24) months of the term loans constitute an interest-only period (with a possible twelve (12) month extension). Subsequent to the interest-only period, the outstanding principal amount of the term loans is repayable in thirty-six (36) equal monthly payments (or twenty-four (24) with the extension). All remaining outstanding principal, together with all accrued and unpaid interest, is due at maturity on February 1, 2028. The term loans may be voluntarily prepaid in full, or in part, at any time, subject to terms and conditions set forth in the Credit Agreement. Additionally, the term loans are subject to mandatory prepayment fees, pursuant to the terms of the Credit Agreement. Prepayments of the term loans are subject to fees of 3%, 2%, and 1% of the prepayment amounts made during the first year, second year, and thereafter, respectively. At the time of the final payment of the term loans, the Company is also obligated to pay an exit fee of 4% of the total amount funded thereunder. The exit fee is being accreted over the life of the Credit Agreement utilizing the effective interest method.
As the Credit Agreement contains a subjective acceleration clause and the Company has experienced recurring losses, outstanding borrowings have been presented as a current liability in the accompanying condensed consolidated balance sheet at March 31, 2023.
Revolving Facility
The Company may borrow, repay and reborrow under the revolving facility until February 1, 2028, at which time the facility will terminate and all outstanding amounts thereunder, including all accrued and unpaid interest, must be repaid. Borrowings are limited to the lesser of the Company’s borrowing base and the revolving commitment of $10,000,000.
In connection with the revolving facility, the Company is required to maintain a lockbox account for the benefit of MidCap. Funds deposited into the lockbox account will be swept daily to MidCap and applied to outstanding borrowings under the revolving agreement 5 days after the receipt of the funds by MidCap. Any balances in excess of the revolving borrowings will be promptly returned to the Company.
Loans made under the revolving facility bear interest at a floating rate based on an adjusted one month SOFR plus 0.1%, subject to a floor of 2.5%, plus 4.00% calculated on a 360 day basis (8.8% at March 31, 2023). The Company is obligated to pay a fee equal to 0.5% per annum on the outstanding balance of the revolving loans and the average unused portion of the available revolving commitments, respectively. Additionally, if the revolving facility is terminated or reduced before maturity, the Company is subject to a deferred origination fee. Terminations and reductions of the commitments are subject to fees of 3%, 2%, and 1% of the terminated or reduced commitments during the first year, second year, and thereafter, respectively. The Company is also required to maintain a minimum balance of 30% of the lesser of the borrowing base or $10 million under the revolving facility. If the average outstanding balance for a month is less than the minimum balance, the Company will pay a minimum balance fee for the difference between the minimum balance and the average outstanding balance for the month at the highest rate for the revolving loans during the month. For such loans, interest and fees are payable monthly on the first day of each month.
As of March 31, 2023, the Company has drawn no amounts on the revolving facility. As of March 31, 2023, the Company had approximately $5,700,000 available to be drawn on the revolving facility. As the Credit Agreement contains a subjective acceleration clause and the Company is required to maintain a lockbox, any amounts drawn on the revolving facility will be presented as a current liability in the consolidated financial statements.
11

Table of Contents
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)
Collateral
The obligations of the Company under the Credit Agreement are secured by first priority liens on substantially all of its assets.
Covenants
The Credit Agreement contains customary affirmative and negative covenants, including covenants limiting the ability of the Company and its subsidiaries, among other things, to incur debt, grant liens, make distributions, enter certain restrictive agreements, pay or modify subordinated debt, dispose of assets, make investments and acquisitions, enter into certain transactions with affiliates, and undergo certain fundamental changes, in each case, subject to limitations and exceptions.
The Credit Agreement also requires the Company to satisfy certain financial covenants, including minimum trailing twelve (12) month net revenue targets relating to its Advanced Energy segment (tested quarterly), with year-end targets of $49 million, $60 million and $70 million for 2023, 2024, and 2025, respectively. Additionally, the Company must maintain a balance of $10 million in cash and cash equivalents during the duration of the Credit Agreement’s term.
As of March 31, 2023, the Company was in compliance with the financial covenants contained within the Credit Agreement.
Events of Default
The Credit Agreement also contains customary Events of Default that include, among other things, certain payment defaults, cross defaults to certain other contracts and indebtedness, covenant defaults, inaccuracy of representations and warranties, bankruptcy and insolvency defaults, judgment defaults, change of control defaults, defaults related to the failure to remain registered with the Securities and Exchange Commission and listed for trading on the Nasdaq Stock Market, and any material adverse change.
Upon the occurrence and during the continuance of an Event of Default under the Credit Agreement, the respective administrative agent, if requested by the respective lenders, may, among other things, (i) suspend or terminate commitments, as well as obligations of the relevant administrative agent and lenders, (ii) declare all outstanding obligations under the agreement (including principal and accrued and unpaid interest) immediately due and payable, and (iii) exercise the other rights and remedies provided for under the agreement. The Credit Agreement provides that, under certain circumstances, a default interest rate will apply on all obligations under such agreement during the existence of an Event of Default, at a per annum rate equal to 2% in excess of the applicable interest rate.
The Company bifurcated a derivative liability related to the potential acceleration triggered upon an event of default (contingent put option) and the supplemental interest upon an event of default features of the Credit Agreement. The bifurcated derivative is de minimis to the Company's unaudited condensed consolidated financial statements.
Issuance of Warrants
In connection with the Company’s obligations under the Credit Agreement, the Company issued to a statutory trust of MidCap Financial warrants to purchase up to 250,000 shares of its common stock, par value $0.001, with an exercise price of $3.40 per share.
The warrants have a 10 year term and can be exercised by issuing payment to the Company for the number of warrants exercised or exercised net by surrendering warrants with an intrinsic value equal to the cumulative exercise price of the warrants being exercised.
The Company determined that these warrants meet the criteria for equity classification and included the proceeds allocated to the warrants, on a relative fair value basis, as a debt discount and additional paid-in capital in the accompanying condensed consolidated financial statements.
Debt Issuance Costs
In connection with entering into the Credit Agreement, the Company incurred debt issuance costs of approximately $1.8 million, comprised primarily of commissions paid to the financial advisor. These costs were allocated to the issued and unissued term loans and the revolving facility. The costs allocated to the issued term loan will be amortized using the effective interest method over the life of the loan. The costs allocated to the unissued term loans have been deferred and will be amortized over the life of the term loans starting at the issuance date. If these loans are not issued, the Company will recognize
12

Table of Contents
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)
the deferred costs at the point that the Company's rights to borrow on the term loans expires. The costs allocated to the revolving facility will be recognized on a straight-line basis over the term of the Credit Agreement.
The costs allocated to the issued term loan have been presented as a reduction of the term loan in the accompanying unaudited condensed consolidated balance sheet. The costs allocated to the unissued term loans and the revolving facility have been presented in prepaid expenses and other current assets in the accompanying unaudited condensed consolidated balance sheet.
Included in interest expense for the three months ended March 31, 2023 are $17,000 and $37,000, respectively, of amortization of the debt issuance costs and amortization of the debt discounts including accretion of the exit fee on the term loan. Included in interest expense for the three months ended March 31, 2023 are $12,000 and $1,000, respectively, of amortization of the debt issuance costs and amortization of the debt discount on the revolving facility.
The Company’s term loan, net consists of the following at March 31, 2023:

(In thousands) |  | March 31, 2023 |  |
Term loan |  | $ | 10,000 |  |  |
Unamortized debt issuance costs |  | (485) |  |  |
Unamortized debt discount, including accretion of exit fee |  | (737) |  |  |
Term loan, net |  | $ | 8,778 |  |  |

As of March 31, 2023, principal repayments on the term loan are as follows:

(In thousands) |
2023 | $ | — |
2024 | — |
2025 | 2,778 |
2026 | 3,333 |
2027 | 3,333 |
Thereafter | 556 |
Total repayments | $ | 10,000 |

NOTE 7. INTEREST IN JOINT VENTURE INVESTMENT
In 2019, the Company executed a joint venture agreement with its Chinese supplier (“China JV”) whereby the Company has a 51% interest. The China JV has been consolidated in these condensed consolidated financial statements. The agreement required the Company to make capital contributions into the newly formed entity of approximately $357,000, of which approximately $203,000 and $154,000, respectively, were contributed during the years ended December 31, 2021 and 2020. As of the date of these condensed consolidated financial statements, the joint venture has not commenced principal operations.
Changes in the Company’s ownership investment in the China JV were as follows:

|  | Three Months Ended March 31, |  |
(In thousands) |  | 2023 |  | 2022 |  |  |  |
Beginning interest in China JV |  | $ | 219 |  |  | $ | 317 |  |  |  |  |
Net loss attributable to Apyx |  | (51) |  |  | (23) |  |  |  |  |
Ending interest in China JV |  | $ | 168 |  |  | $ | 294 |  |  |  |  |

13

Table of Contents
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)
NOTE 8. EARNINGS (LOSS) PER SHARE
Basic earnings (loss) per share (“basic EPS”) is computed by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period. Diluted earnings (loss) per share (“diluted EPS”) gives effect to all dilutive potential shares outstanding. As the Company is in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. The following table provides the computation of basic and diluted loss per share.

|  | Three Months Ended March 31, |  |  |  |
(in thousands, except per share data) |  | 2023 |  | 2022 |  |  |  |  |  |
Numerator: |  |  |  |  |  |  |  |  |  |
Net loss attributable to stockholders |  | $ | (3,483) |  |  | $ | (5,945) |  |  |  |  |  |  |
Denominator: |  |  |  |  |  |  |  |  |  |
Weighted average shares outstanding - basic and diluted |  | 34,598 |  |  | 34,429 |  |  |  |  |  |  |
Loss per share: |  |  |  |  |  |  |  |  |  |
Basic and diluted |  | $ | (0.10) |  |  | $ | (0.17) |  |  |  |  |  |  |
Anti-dilutive instruments excluded from diluted loss per common share: |  |  |  |  |  |  |  |  |  |
Options |  | 7,783 |  |  | 6,796 |  |  |  |  |  |  |
Warrants |  | 250 |  |  | — |  |  |  |  |  |  |

14

Table of Contents
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)
NOTE 9. STOCK-BASED COMPENSATION
Under the Company's stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, Compensation - Stock Compensation, with stock-based compensation expense recognized over the vesting period based on the grant date fair value utilizing the Black Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.
The Company recognized approximately $1,367,000 in stock-based compensation expense for the three months ended March 31, 2023, as compared with $1,650,000 for the three months ended March 31, 2022.
Stock option activity is summarized as follows:

| Number of options |  | Weighted average exercise price
Outstanding at December 31, 2022 | 6,520,444 |  |  | $ | 7.12 |
Granted | 1,408,865 |  |  | 2.50 |
Exercised | — |  |  | — |
Canceled and forfeited | (146,164) |  |  | 8.08 |
Outstanding at March 31, 2023 | 7,783,145 |  |  | $ | 6.27 |

The Company allows stock option holders to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of the stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. For the three months ended March 31, 2022, we received 22,654 options as payment in the exercise of 19,013 options. There were no such exercises for the three months ended March 31, 2023.
Common shares required to be issued upon the exercise of stock options would be issued from authorized and unissued shares. The Company calculated the grant date fair value of options granted in 2023 (“2023 Grants”) utilizing a Black Scholes model.

| 2023 Grants |  |  |  |
Strike price | $2.50 |  |  |  |  |  |  |  |  |  |
Risk-free rate | 3.6% |  |  |  |  |  |  |  |
Expected dividend yield | — |  |  |  |
Expected volatility | 85.8% |  |  |  |  |  |  |  |  |  |
Expected term (in years) | 6 |  |  |  |  |  |  |  |

NOTE 10. INCOME TAXES
Income tax (benefit) expense was approximately $(2,267,000) and $70,000 with effective tax rates of 39.1% and (1.2)% for the three months ended March 31, 2023 and 2022, respectively. For the three months ended March 31, 2023, the effective rate differs from the statutory rate primarily due to the reversal of the Company’s liability for uncertain tax positions, including accrued interest and penalties of approximately $2.1 million which were sustained upon the completion in January 2023 of the IRS examination of our 2018 through 2020 income tax returns, partially offset by a valuation allowance on the net operating loss (“NOL”) and net deferred tax assets generated during the period. For the three months ended March 31, 2022, the effective rate differs from the statutory rate primarily due to the full valuation allowance recorded on the NOL generated during the period, combined with interest and penalties on uncertain tax positions.
15

Table of Contents
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)
NOTE 11. COMMITMENTS AND CONTINGENCIES
Litigation
The medical device industry is characterized by frequent claims and litigation, and the Company may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims.
The Company is involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within the Company’s control and may not be known for prolonged periods of time. It believes that such claims are adequately covered by insurance; however, in the case of one of the Company’s carriers, the Company is in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses, and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on its financial condition, results of operations and cash flows. However, in the event that damages exceed the aggregate coverage limits of the Company’s policies or if its insurance carriers disclaim coverage, management believes it is possible that costs associated with these claims could have a material adverse impact on the consolidated financial condition, results of operations and cash flows.
The Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates.
During December 2021, the Company provided notice of contract termination to an international distributor of the Company. In March 2022, the Company received a letter from the former distributor citing improper contract termination and alleging damages. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $250,000 to $1,000,000. The Company recorded an estimated loss of $250,000 related to the matter during 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.
As previously disclosed with the U.S. Securities and Exchange Commission on the Company’s Current Report on Form 8-K filed June 7, 2022, on June 6, 2022, a complaint (the “Hattaway Complaint”) was filed in the United States District Court for the Middle District of Florida by plaintiff William E. Hattaway, individually and on behalf of all others similarly situated against the Company, Charles D. Goodwin (“Goodwin”), the Company’s President and Chief Executive Officer and a member of the Company’s Board of Directors, and Tara Semb (“Semb”), the Company’s Chief Financial Officer, Treasurer and Secretary, alleging violations by the Company, Goodwin and Semb of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, primarily related to certain public statements and disclosures concerning the off-label usage of certain of the Company’s Advanced Energy products and the impact such usage would have on the Company’s business, operations and prospects. The Hattaway Complaint seeks an unspecified amount of damages.
Although the ultimate outcome of this matter cannot be determined with certainty, the Company believes that the allegations stated in the Hattaway Complaint are without merit. The Company, Goodwin and Semb intend to defend themselves vigorously in the suit. In the opinion of management, such claims are adequately covered by insurance, however, in the event that damages exceed the aggregate coverage limits of our policy or if our insurance carriers disclaim coverage, we believe it is possible that costs associated with this claim could have a material adverse impact on our consolidated results of operations, financial position or cash flows. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $475,000 to $2,500,000. The Company recorded an estimated loss of $475,000 related to the matter during 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.
During 2022, the Company was notified of certain procedures alleged to have been performed by the same physician and which are currently the subject of two related products liability cases within the courts. Subsequent to year end, the Company was notified by its insurance carriers that all or most of the ten individual plaintiff’s allegations could be subject to separate
16

Table of Contents
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)
deductibles notwithstanding the commonality of each underlying occurrence. The Company has determined that a loss is probable and that a range of estimated losses is approximately $1,450,000 to $2,400,000. The Company recorded an estimated loss of $1,450,000 related to the matters during 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.
On March 1, 2023, Shiva Stein as plaintiff filed a derivative complaint in the Court of Chancery of the State of Delaware, captioned Stein v. Makrides, et al., C.A. No. 2023-0239-MTZ (the “Stein Suit”) against individual members of the Company’s board of directors and naming the Company as a nominal defendant, primarily concerning the facts at issue in a previously disclosed federal securities class action lawsuit filed in 2019 and settled in 2020, captioned Pritchard v. Apyx Medical Corporation, et al., Case No. 8:19-cv-00919 (M.D. Fla.) (the “Pritchard Case”). The Stein Suit seeks unspecified damages alleged to have resulted from purported breaches of fiduciary duty, unjust enrichment and related claims based on the same set of allegedly misleading statements and material omissions described in the settled Pritchard Case, which concerned the 2018-2019 clinical study conducted by the Company to evaluate the safety and efficacy of its J-Plasma technology for dermal resurfacing. The Company believes that the claims are subject to procedural and substantive defenses, anticipates defense and indemnity coverage to be made available by the relevant insurer, and expects the individual defendants to defend all of the allegations vigorously. The outcome of the action is not within the Company’s control and may not be known for a prolonged period of time. In the opinion of management, neither the alleged claims against the individual defendants nor the defense thereof are expected to result in a material, adverse effect on the Company’s financial condition, results of operations and cash flows.
Purchase Commitments
At March 31, 2023, the Company had purchase commitments totaling approximately $4.0 million, substantially all of which is expected to be purchased within the next twelve months.
17

Table of Contents
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)
NOTE 12. RELATED PARTY TRANSACTIONS
Several relatives of Nikolay Shilev, Apyx Bulgaria’s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev’s spouse, is an employee of the Company working in the accounting department. Svetoslav Shilev, Mr. Shilev’s son, is a quality manager in the quality assurance department.
The partner in the Company's China JV is also a supplier to the Company. For the three months ended March 31, 2023 and 2022, the Company made purchases from this supplier of approximately $44,000 and $124,000, respectively. At March 31, 2023 and December 31, 2022, respectively, the Company had net payables to and receivables from this supplier approximately $2,000 and $8,000, respectively.
NOTE 13. GEOGRAPHIC AND SEGMENT INFORMATION
Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, the Company also considers the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to its chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, the Company has not presented a measure of assets by segment.
The Company's reportable segments are disclosed as principally organized and managed as two operating segments: Advanced Energy and OEM. "Corporate & Other" includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.
Summarized financial information with respect to reportable segments is as follows:
18

Table of Contents
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)

|  |  | Three Months Ended March 31, 2023
(In thousands) |  |  | Advanced Energy |  | OEM |  | Corporate & Other |  | Total
Sales |  |  | $ | 9,690 |  |  | $ | 2,452 |  |  | $ | — |  |  | $ | 12,142 |
Income (loss) from operations |  |  | (1,326) |  |  | 851 |  |  | (5,136) |  |  | (5,611) |
Interest income |  |  | — |  |  | — |  |  | 51 |  |  | 51 |
Interest expense |  |  | — |  |  | — |  |  | (234) |  |  | (234) |
Other loss, net |  |  | — |  |  | — |  |  | (5) |  |  | (5) |
Income tax benefit |  |  | — |  |  | — |  |  | (2,267) |  |  | (2,267) |

|  |  | Three Months Ended March 31, 2022
(In thousands) |  |  | Advanced Energy |  | OEM |  | Corporate & Other |  | Total
Sales |  |  | $ | 10,814 |  |  | $ | 1,679 |  |  | $ | — |  |  | $ | 12,493 |
Income (loss) from operations |  |  | (1,339) |  |  | 317 |  |  | (4,849) |  |  | (5,871) |
Interest income |  |  | — |  |  | — |  |  | 2 |  |  | 2 |
Interest expense |  |  | — |  |  | — |  |  | (8) |  |  | (8) |
Other loss, net |  |  | — |  |  | — |  |  | (21) |  |  | (21) |
Income tax expense |  |  | — |  |  | — |  |  | 70 |  |  | 70 |

International sales represented approximately 26.9% of total revenues for the three months ended March 31, 2023, as compared with approximately 39.6% of total revenues for the three months ended March 31, 2022.
Revenue by geographic region, based on the customer's “ship to” location on the invoice, are as follows:

| Three Months Ended March 31, |  |
(In thousands) | 2023 |  | 2022 |  |  |  |
Sales by Domestic and International |  |  |  |  |  |  |
Domestic | $ | 8,871 |  |  | $ | 7,548 |  |  |  |  |
International | 3,271 |  |  | 4,945 |  |  |  |  |
Total | $ | 12,142 |  |  | $ | 12,493 |  |  |  |  |

19

Table of Contents
APYX MEDICAL CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion and analysis in conjunction with our financial statements and related notes contained elsewhere in this report. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors discussed in this report and those discussed in other documents we file with the SEC. In light of these risks, uncertainties and assumptions, readers are cautioned not to place undue reliance on such forward-looking statements. These forward-looking statements represent beliefs and assumptions as of the date of this report. While we may elect to update forward-looking statements and at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. Past performance does not guarantee future results.
Executive Level Overview
We are an advanced energy technology company with a passion for elevating people’s lives through innovative products, including our Helium Plasma Technology products marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion® and J-Plasma® offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. We also leverage our deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers.
As part of our plan to accelerate and fully fund the development of our advanced energy business, with a focus in the cosmetic surgery market, we sold our Core business in 2018 for gross proceeds of $97 million. These proceeds were used to launch broad marketing and sales initiatives which resulted in rapid sales growth through December 31, 2021 and into the first quarter of 2022. This planned growth in the business was accompanied by scaled operations, including procurement of components, expanded manufacturing capacity to turn those materials into saleable inventory, additional discretionary expenditures, including increased global participation at trade shows, additional employee trainings, user meetings, increased travel and entertainment expenses, more expansive research and development projects, and additional headcount to support those activities. Additionally, we had and still have, some significant non-recurring discretionary expenditures associated with completing our multi-year marketing initiatives related to our dermal resurfacing and skin laxity clearances.
On March 14, 2022, the U.S. Food and Drug Administration (“FDA”) posted a Medical Device Safety Communication (“Safety Communication”). The FDA warned against the use of Renuvion/J-Plasma for procedures intended to improve the appearance of the skin through dermal resurfacing (a procedure on the skin to treat wrinkles) or skin contraction (a procedure under the skin that can be performed either alone or in combination with liposuction to achieve skin effects, such as “tightening”). At that time, the Renuvion/J-Plasma device system was FDA cleared for general use of cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures. The use of the device had not been determined to be safe or effective for any aesthetic skin procedures (procedures intended to improve the appearance of the skin). Following the Safety Communication, we experienced slowed demand for the adoption of its Helium Plasma Technology.
On May 26, 2022, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion® Dermal Handpiece for certain dermal resurfacing procedures, specifically, for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick Skin Types I, II or III.
On June 2, 2022, the FDA updated the Safety Communication to inform consumers and healthcare providers about the new 510(k) clearance for the Renuvion® device system for certain dermal resurfacing procedures.
On July 18, 2022, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for use in subcutaneous dermatological and aesthetic procedures to improve the appearance of lax (loose) skin in the neck and submental (under the chin) region.
On July 21, 2022, the FDA updated the Safety Communication to inform consumers and healthcare providers about the clearance for the Renuvion® APR handpieces for use under the skin in certain procedures intended to improve the appearance of loose skin.
On February 27, 2023, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue.
20

Table of Contents
APYX MEDICAL CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued
On April 28, 2023, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.
On May 10, 2023, the FDA updated the Safety Communication to inform consumers and healthcare providers about the clearance for the Renuvion® APR handpiece for use under the skin in certain procedures intended to improve the appearance of the skin, including for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.
We believe that the May 10, 2023 FDA update to the Safety Communication addresses the issues set forth in the original Safety Communication from March 14, 2022. While no assurances can be provided, we believe that receiving these additional clearances and the corresponding updates to the Safety Communication since March 14, 2022 should mitigate the financial effects of the Safety Communication in future periods.
While sales were continuing to grow into the first quarter of 2022 prior to the FDA Safety Communication, over the last few years, exclusive of our sale of the Core business segment to Symmetry Surgical during 2018, we have incurred recurring net losses and cash outflows from operations and we anticipate that losses will continue in the near term. During the year ended December 31, 2022, the we incurred an operating loss of $23.6 million and used $20.3 million of cash in operations. During the three months ended March 31, 2023, the we incurred an operating loss of $5.6 million and used $1.9 million of cash in operations. As of March 31, 2023, the we had cash and cash equivalents of $16.3 million, of which we must maintain $10.0 million under our Credit Agreement. These conditions raise substantial doubt about our ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements.
In an effort to alleviate these conditions, we pursued various funding solutions in order to improve liquidity.
On November 22, 2022, the we filed a shelf registration statement providing us the ability to register securities in the aggregate amount up to $100 million. The shelf registration included an embedded ATM facility for up to $40 million. To date, we have not utilized this facility.
On February 17, 2023, we entered into a Credit, Security and Guaranty Agreement (the “Credit Agreement”) with MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time.
The Credit Agreement provides for an up to $35 million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provides for senior secured term loans of up to $25 million, comprised of (i) an initial tranche of $10 million, (ii) a second tranche of $5 million, and (iii) a third tranche of $10 million. The secured revolving facility provides for loans in an aggregate principal amount of up to $10 million, subject to a borrowing base equal to certain percentages of the Company’s eligible accounts receivable and inventory, as determined in accordance with the terms of the Credit Agreement.
For a more in depth description of the terms of the Credit Agreement, see Note 6 of Notes to Condensed Consolidated Financial Statements in Item 1 of this report on Form 10-Q.
On February 27, 2023, our Board of Directors approved a plan to sell and leaseback the our real property located in Clearwater, FL. On March 14, 2023, we entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with VK Acquisitions VI, LLC (the “Purchaser”), for the sale of our facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the “Property”) for a purchase price of $7,650,000. The Purchase Agreement is subject to the satisfactory completion of due diligence by the Purchaser. On May 8, 2023, we closed on the Purchase Agreement and concurrently executed a 10-year agreement to leaseback the underlying Property from the Purchaser.
For a more in depth description of the terms of the Purchase Agreement, see Note 4 of Notes to Condensed Consolidated Financial Statements in Item 1 of this report on Form 10-Q.
During January 2023, we were notified that the IRS examination process of our 2018, 2019 and 2020 tax returns was complete and that the our tax refunds were approved for approximately $0.2 million more than the amount recorded in the Company’s Consolidated Balance Sheet at December 31, 2022. As of the date of this report, we are awaiting receipt of the tax refunds.
21

Table of Contents
APYX MEDICAL CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued
We also continue to re-assess our operating expenditures and cost structure to be commensurate with our expected levels of revenue and we have the ability to reduce or delay expenditures to enhance and preserve liquidity. We have already reduced some operating expenditures, including a reduction-in-force on January 9, 2023, that reduced our U.S. headcount by 14%.
We believe that the actions already taken, and additional actions that we intend to take to manage operating expenditures, will enable us to meet our obligations and our debt covenants for a period of at least one year from the date of issuance of our audited consolidated financial statements. As a result, we believe our plans alleviate substantial doubt about our ability to continue as a going concern. Our audited financial statements do not include any adjustments relating to the carrying amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern.
We continue to drive sales in our Advanced Energy business by increasing the adoption and utilization of our handpieces by surgeons in the U.S. and fulfilling demand from distributors in our international markets. Management estimates that our products have been sold in more than 60 countries. As of March 31, 2023, we had a direct sales force of 35 field-based selling professionals and utilized 3 independent sales agencies. We also had 4 sales managers. This selling organization is focused on the use of Renuvion® in the cosmetic surgery market, supported by our global medical affairs team. This global team of clinical support specialists focuses on supporting our users to ensure optimal outcomes for their patients. In addition, we have invested in training programs and marketing-related activities to support accelerated adoption of Renuvion® into physicians’ practices.
In regards to our operating segments, our results are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, we also consider the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to our chief operating decision maker for operating and administrative activities, availability of discrete financial information, and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment and, accordingly, we have not presented a measure of assets by reportable segment.
Our reportable segments are disclosed as principally organized and managed as two operating segments: Advanced Energy and OEM. "Corporate & Other" includes certain unallocated corporate and administrative costs which are not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, and all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.
In response to the global supply chain instability and inflationary cost increases, we continue to take action to minimize, as much as possible, any potential adverse impacts by working closely with our suppliers to closely monitor the availability of raw material components (i.e. semiconductors and plastics), lead times, and freight carrier availability. We expect global supply chain instability will continue to have an impact on our business, but to date that has not been material to our financial performance. The consequences of the pandemic, global supply chain instability and inflationary cost increases and their adverse impact to the global economy, continue to evolve. Accordingly, the significance of the future impact to our business and financial statements remains subject to significant uncertainty.
We strongly encourage investors to visit our website: www.apyxmedical.com to view the most current news and to review our filings with the Securities and Exchange Commission.
Results of Operations
Sales
22

Table of Contents
APYX MEDICAL CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued

| Three Months Ended March 31, |  |  |  |  |  |  |
(In thousands) | 2023 |  | 2022 |  | Change |  |  |  |  |  |  |
Sales by Reportable Segment |  |  |  |  |  |  |  |  |  |  |  |
Advanced Energy | $ | 9,690 |  |  | $ | 10,814 |  |  | (10.4) | % |  |  |  |  |  |  |
OEM | 2,452 |  |  | 1,679 |  |  | 46.0 | % |  |  |  |  |  |  |
Total | $ | 12,142 |  |  | $ | 12,493 |  |  | (2.8) | % |  |  |  |  |  |  |
Sales by Domestic and International |  |  |  |  |  |  |  |  |  |  |  |
Domestic | $ | 8,871 |  |  | $ | 7,548 |  |  | 17.5 | % |  |  |  |  |  |  |
International | 3,271 |  |  | 4,945 |  |  | (33.9) | % |  |  |  |  |  |  |
Total | $ | 12,142 |  |  | $ | 12,493 |  |  | (2.8) | % |  |  |  |  |  |  |

Total revenue decreased by 2.8%, or approximately $0.4 million, for the three months ended March 31, 2023 when compared with the three months ended March 31, 2022. Advanced Energy segmen t sales decreased 10.4%, or approximately $1.1 million, for the three months ended March 31, 2023 when compared with the three months ended March 31, 2022. The Advanced Energy sales decrease was driven by decreases in adoption of our generator technology in international markets and in global utilization based demand for our handpieces following the FDA Safety Communication on March 14, 2022. These decreases were partially offset by domestic customers, who upgraded their generator to our new Apyx One Console, which we launched in January 2023.
OEM segmen t sales increased 46.0%, or approximately $0.8 million, for the three months ended March 31, 2023 when compared with the three months ended March 31, 2022. The increase in OEM sales was due to increases in sales volume to existing customers as well as incremental new sales upon the commencement of the supply arrangement related to the completion of the development portion of some of our OEM development agreements.
International sales represented approximately 26.9% of total revenues for the three months ended March 31, 2023, as compared with 39.6% of total revenues for the same prior year period. Management estimates our products have been sold in more than 60 countries through local dealers coordinated by sales and marketing personnel through our facilities in Clearwater, Florida and Sofia, Bulgaria.
Gross Profit

| Three Months Ended March 31, |  |  |  |  |  |
(In thousands) | 2023 |  | 2022 |  | Change |  |  |  |  |  |
Cost of sales | $ | 4,569 |  |  | $ | 4,274 |  |  | 6.9 | % |  |  |  |  |  |
Percentage of sales | 37.6 | % |  | 34.2 | % |  |  |  |  |  |  |  |

Gross profit | $ | 7,573 |  |  | $ | 8,219 |  |  | (7.9) | % |  |  |  |  |  |
Percentage of sales | 62.4 | % |  | 65.8 | % |  |  |  |  |  |  |  |

Gross profit for the three months ended March 31, 2023, decreased 7.9% to $7.6 million, compared to $8.2 million for the same period in the prior year. Gross margin for the three months ended March 31, 2023, was 62.4%, compared to 65.8% for the same period in 2021.
The decrease in gross profit margins for the three months ended March 31, 2023 from the prior year period is primarily attributable to changes in the sales mix between our two segments, with our OEM segment comprising a higher percentage of total sales and product mix within our Advanced Energy segment. These decreases were partially offset by geographic mix within our Advanced Energy segment, with domestic sales comprising a higher percentage of total sales.
Other Costs and Expenses
23

Table of Contents
APYX MEDICAL CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued
Research and development

| Three Months Ended March 31, |  |  |  |  |  |
(In thousands) | 2023 |  | 2022 |  | Change |  |  |  |  |  |
Research and development expense | $ | 1,121 |  |  | $ | 1,158 |  |  | (3.2) | % |  |  |  |  |  |
Percentage of sales | 9.2 | % |  | 9.3 | % |  |  |  |  |  |  |  |

Research and development expenses decreased 3.2% for the three months ended March 31, 2023, primarily due to lower spending on ou r two investigational device exemption (IDE) clinical studies and other product development initiatives ($0.1 million). This decrease was partially offset by increased labor and benefit costs from the same period in the prior year ($0.1 million).
Professional services

| Three Months Ended March 31, |  |  |  |  |  |
(In thousands) | 2023 |  | 2022 |  | Change |  |  |  |  |  |
Professional services expense | $ | 1,740 |  |  | $ | 2,286 |  |  | (23.9) | % |  |  |  |  |  |
Percentage of sales | 14.3 | % |  | 18.3 | % |  |  |  |  |  |  |  |

Professional ser vices expense decreased 23.9% for the three months ended March 31, 2023 as compared to the same period in the prior year, primarily attributable to decreases in legal expenses ($0.3 million), physician consulting fees ($0.2 million) and accounting and audit fees ($0.1 million).
Salaries and related costs

| Three Months Ended March 31, |  |  |  |  |  |
(In thousands) | 2023 |  | 2022 |  | Change |  |  |  |  |  |
Salaries and related expenses | $ | 5,068 |  |  | $ | 5,181 |  |  | (2.2) | % |  |  |  |  |  |
Percentage of sales | 41.7 | % |  | 41.5 | % |  |  |  |  |  |  |  |

During the three months ended March 31, 2023, salaries and related expenses decreased 2.2%, primarily driven by lower stock based compensation expense ($0.2 million). This increase was partially offset by higher compensation and benefits ($0.1 million) as compared to the same period in the prior year.
Selling, general and administrative expenses

| Three Months Ended March 31, |  |  |  |  |  |
(In thousands) | 2023 |  | 2022 |  | Change |  |  |  |  |  |
SG&A expense | $ | 5,255 |  |  | $ | 5,465 |  |  | (3.8) | % |  |  |  |  |  |
Percentage of sales | 43.3 | % |  | 43.7 | % |  |  |  |  |  |  |  |

During the three months ended March 31, 2023, selling, general and administrative expense decreased 3.8%, primarily driven by decreased advertising expense, including trade show fees and related costs ($0.5 million), lower bad debt expenses ($0.3 million) and employee training and other meeting expenses ($0.2 million). These decreases were partially offset by increases in travel and entertainment expense ($0.5 million) and insurance expense ($0.3 million).
24

Table of Contents
APYX MEDICAL CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued
Interest Income (Expense)

| Three Months Ended March 31, |  |  |  |  |  |
(In thousands) | 2023 |  | 2022 |  |  |  |  |  |  |  |
Interest income | $ | 51 |  |  | $ | 2 |  |  |  |  |  |  |  |  |
Percentage of sales | 0.4 | % |  | — | % |  |  |  |  |  |  |  |
Interest expense | (234) |  |  | (8) |  |  |  |  |  |  |  |  |
Percentage of sales | (1.9) | % |  | (0.1) | % |  |  |  |  |  |  |  |

Interest income increased approximately $0.1 million for the three months ended March 31, 2023, compared with same period in the prior year. This increase is due to higher yields on our investments in money market funds and U.S. Treasury securities included in cash, cash equivalents and restricted cash, partially offset by a lower average balance.
Interest expense increased approximately $0.2 million for the three months ended March 31, 2023, compared with same period in the prior year. This increase is due to cash and noncash interest expense on the Credit Agreement executed on February 17, 2023.
Income Taxes

| Three Months Ended March 31, |  |  |  |  |  |
(In thousands) | 2023 |  | 2022 |  |  |  |  |  |  |  |
Income tax (benefit) expense | $ | (2,267) |  |  | $ | 70 |  |  |  |  |  |  |  |  |
Effective tax rate | 39.1 | % |  | (1.2) | % |  |  |  |  |  |  |  |

Our income tax (benefit) expense was approximately $(2,267,000) and $70,000 with effective tax rates of 39.1% and (1.2)% for the three months ended March 31, 2023 and 2022, respectively. For the three months ended March 31, 2023, the effective rate differs from the statutory rate primarily due to the reversal of our liability for uncertain tax positions, including accrued interest and penalties, of approximately $2.1 million which were sustained upon the completion in January 2023 of the IRS examination of our 2018 through 2020 income tax returns, partially offset by a valuation allowance on our NOL and net deferred tax assets generated during the period. For the three months ended March 31, 2022, the effective rate differs from the statutory rate primarily due to the full valuation allowance recorded on the NOL generated during the period, combined with interest and penalties on uncertain tax positions.
Liquidity and Capital Resources
At March 31, 2023, we had approximately $16.3 million in cash, cash equivalents and restricted cash as compared to approximately $10.2 million in cash and cash equivalents at December 31, 2022. Our working capital at March 31, 2023 was approximately $34.2 million compared with $31.1 million at December 31, 2022. The increase in working capital at March 31, 2023 was primarily due to the reclassification of assets held for sale from long term assets to current assets in March 2023 and the reversal of our liability for uncertain tax positions upon the completion in January 2023 of the IRS examination of our 2018, 2019 and 2020 income tax returns. This increase was partially offset by the net loss incurred by the Company in the first quarter of 2023, excluding non-cash activity, comprised primarily of stock-based compensation.
For the three months ended March 31, 2023, net cash used in operating activities was approximately $1.9 million, which principally funded our los s from operations of $5.6 million, compared with net cash used in operating activities of approximately $4.5 million in 2022. As discussed in the Executive Level Overview, our operating loss, cash used in operations and current cash and cash equivalents balance of $16.3 million, of which we must maintain $10.0 million under our Credit Agreement, raise substantial doubt about our ability to continue as a going concern for a period of at least one year from the date of issuance of our unaudited condensed consolidated financial statements.
In an effort to alleviate these conditions, we pursued various funding solutions in order to improve liquidity.
25

Table of Contents
APYX MEDICAL CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued
On November 22, 2022, the we filed a shelf registration statement providing us the ability to register securities in the aggregate amount up to $100 million. The shelf registration included an embedded ATM facility for up to $40 million. To date, we have not utilized this facility.
On February 17, 2023, we entered into a Credit, Security and Guaranty Agreement (the “Credit Agreement”) with MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time.
The Credit Agreement provides for an up to $35 million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provides for senior secured term loans of up to $25 million, comprised of (i) an initial tranche of $10 million, (ii) a second tranche of $5 million, and (iii) a third tranche of $10 million. The secured revolving facility provides for loans in an aggregate principal amount of up to $10 million, subject to a borrowing base equal to certain percentages of the Company’s eligible accounts receivable and inventory, as determined in accordance with the terms of the Credit Agreement.
For a more in depth description of the terms of the Credit Agreement, see Note 6 of Notes to Condensed Consolidated Financial Statements in Item 1 of this report on Form 10-Q.
On February 27, 2023, our Board of Directors approved a plan to sell and leaseback the our real property located in Clearwater, FL. On March 14, 2023, we entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with VK Acquisitions VI, LLC (the “Purchaser”), for the sale of our facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the “Property”) for a purchase price of $7,650,000. On May 8, 2023, we closed on the Purchase Agreement and concurrently executed a 10-year agreement to leaseback the underlying Property from the Purchaser.
For a more in depth description of the terms of the Purchase Agreement, see Note 4 of Notes to Condensed Consolidated Financial Statements in Item 1 of this report on Form 10-Q.
During January 2023, we were notified that the IRS examination process of our 2018, 2019 and 2020 tax returns was complete and that the Company's tax refunds were approved for approximately $0.2 million more than the amount recorded in the Company's Consolidated Balance Sheet at December 31, 2022. As of the date of this report, we are awaiting receipt of the tax refunds.
We also continue to re-assess our operating expenditures and cost structure to be commensurate with our expected levels of revenue and we have the ability to reduce or delay expenditures to enhance and preserve liquidity. We have already reduced some operating expenditures, including a reduction-in-force on January 9, 2023, that reduced our U.S. headcount by 14%.
We believe that the actions already taken, and additional actions that we intend to take to manage operating expenditures, will enable us to meet our obligations and our debt covenants for a period of at least one year from the date of issuance of our audited consolidated financial statements. As a result, we believe our plans alleviate substantial doubt about our ability to continue as a going concern. Our audited financial statements do not include any adjustments relating to the carrying amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern.
Net cash used in investing activities for the three months ended March 31, 2023 and 2022, were $0.1 million and $0.3 million, respectively, related to purchases of property and equipment.
Net cash provided by financing activities for the three months ended March 31, 2023 was $8.1 million related to proceeds received upon the execution of the Credit Agreement ($9.9 million) less debt issuance costs incurred in the transaction ($1.8 million).
At March 31, 2023, our borrowing availability under the revolving facility was approximately $5.7 million.
At March 31, 2023, we had purchase commitments for inventories totaling approximately $4.0 million, substantially all of which is expected to be purchased by the end of 2023.
26

Table of Contents
APYX MEDICAL CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued
Critical Accounting Estimates
In preparing the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP), we have adopted various accounting policies. Our most significant accounting policies are disclosed in Note 2 to the consolidated financial statements included in our 2022 Form 10-K, filed with the SEC on March 16, 2023.
The preparation of the consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Our estimates and assumptions, including those related to inventories, intangible assets, property, plant and equipment, legal proceedings, research and development, warranty obligations, product liability, sales returns and discounts, stock-based compensation and income taxes are updated as appropriate, which in most cases is at least quarterly. We base our estimates on historical experience, or various assumptions that are believed to be reasonable under the circumstances and the results form the basis for making judgments about the reported values of assets, liabilities, revenues and expenses. Actual results may materially differ from these estimates.
Estimates are considered to be critical if they meet both of the following criteria: (1) the estimate requires assumptions about material matters that are uncertain at the time the accounting estimates are made and (2) other materially different estimates could have been reasonably made or material changes in the estimates are reasonably likely to occur from period to period. Our critical accounting estimates include the following:
Stock-Based Compensation
Under our stock option plans, options to purchase common shares of the Company may be granted to employees, officers and directors of the Company by the Board of Directors. We account for stock options in accordance with FASB ASC Topic 718-10, Compensation-Stock Compensation, with compensation expense recognized over the vesting period. Options are valued using the Black-Scholes model, which includes a number of estimates that affect the amount of our expense. We have determined that the most critical of these estimates are the estimates of expected life and volatility used in the calculations.
Expected life
For employee stock-based compensation awards, we estimate the expected life of awards utilizing the SEC's simplified method. We utilize this method, as we have not historically granted stock-based compensation awards to employees in sufficient volumes to determine a reasonable estimate of the life of awards. For awards granted to non-employees, we calculate expected life using a combination of past exercise behavior, the contractual term and expected remaining exercise behavior.
Volatility
We determine the volatility by utilizing the historical volatility of our stock over the period of the awards expected life. The SEC allows us to include periods in excess of the useful life if we determine that they provide a more reasonable basis for the volatility of our stock. Additionally, ASC 718-10 allows us to exclude periods from the volatility if they pertain to events or circumstances that in our judgment are specific to us and if the event or transaction is not reasonably expected to occur again during the expected term of the awards. We have not included any additional periods, nor disregarded any periods, in calculating our volatility.
Accounts Receivable Allowance
We maintain a reserve for uncollectible accounts receivable. When evaluating the adequacy of the allowance for doubtful accounts, we analyze historical bad debt experience, the composition of outstanding receivables by customer class, and the age of outstanding balances, and we make estimates in connection with establishing the allowance for doubtful accounts, including the expected impacts of changes in the operating environment and other trends. Changes in estimates are reflected in the period they are made. If the financial condition of our customers deteriorates, resulting in an inability to make payments, additional allowances may be required.
27

Table of Contents
APYX MEDICAL CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued
Inventory Obsolescence Allowance
We maintain a reserve for excess and obsolete inventory resulting from the potential inability to sell our products at prices in excess of current carrying costs. The markets in which we operate are highly competitive, with new products and surgical procedures introduced on an ongoing basis. Such marketplace changes may cause our products to become obsolete. We make estimates regarding the future recoverability of the costs of these products and record a provision for excess and obsolete inventories based on historical experience and expected future trends. If actual product life cycles, product demand or acceptance of new product introductions are less favorable than projected by management, additional inventory write-downs may be required, which would unfavorably affect future operating results.
Litigation Contingencies
In accordance with authoritative guidance, we record a liability in our consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded; actual results may differ from these estimates.
Income Taxes
The provision for income taxes includes federal, foreign, state and local income taxes currently payable and those deferred because of temporary differences between the financial statement and tax bases of assets and liabilities. Deferred tax assets or liabilities are computed based on the difference between the financial statement and income tax bases of assets and liabilities using enacted marginal tax rates. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. Deferred income tax expenses or credits are based on the changes in the asset or liability from period to period.
As a result of historical losses and our expectation to continue to generate losses in the near future, we recorded a valuation allowance on our net deferred tax assets. Exclusive of the carryback provisions of the CARES Act and the associated income tax benefit recognized in 2020, we do not anticipate recording an income tax benefit related to our deferred tax assets. We will reassess the realization of deferred tax assets each reporting period and will be able to reduce the valuation allowance to the extent our results of operations improve, and it becomes more likely than not that the deferred tax assets will be realized. As Management has not fully determined the timing of when it will generate taxable income in the U.S., we continued to record a valuation allowance on the net deferred tax assets balance as of March 31, 2023.
We assess the financial statement impact of an uncertain tax position taken or expected to be taken on an income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained.
Inflation
The consequences of the pandemic, global supply chain instability and inflationary cost increases and their adverse impact to the global economy, continue to evolve. Accordingly, the significance of the future impact to our business and financial statements remains subject to significant uncertainty. Inflation has not, to date, materially impacted our operations or financial performance. However, as these trends continue for raw materials, freight, and labor costs, our future financial performance could be adversely impacted.
Off-Balance Sheet Arrangements
We have no off-balance sheet arrangements at this time.
Recent Accounting Pronouncements
See Note 2 of the Notes to Condensed Consolidated Financial Statements.
28

Table of Contents
APYX MEDICAL CORPORATION
ITEM 3. Quantitative and Qualitative Disclosures about Market Risk
Not applicable.
29

Table of Contents
APYX MEDICAL CORPORATION
ITEM 4. Controls and Procedures
Disclosure Controls and Procedures
Our management has established and maintains disclosure controls and procedures that are designed to ensure that the information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Management carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of March 31, 2023, the Company's disclosure controls and procedures were effective.
Changes in Internal Control Over Financial Reporting
In February 2023, we entered into a Credit, Security and Guaranty Agreement ("Credit Agreement"). We are in the process of developing new control activities around the accounting for the Credit Agreement, including the review and compliance with debt covenants. There were no other changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by the Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
30

Table of Contents
APYX MEDICAL CORPORATION
PART II. Other Information
ITEM 1. Legal Proceedings
See Note 1 1 of Notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q.
31

Table of Contents
APYX MEDICAL CORPORATION
ITEM 1A. Risk factors
There have been no material changes to the risk factors described under Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.
32

Table of Contents
APYX MEDICAL CORPORATION
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
ITEM 3. Defaults Upon Senior Securities
None.
ITEM 4. Mine Safety Disclosures
Not Applicable.
ITEM 5. Other Information
On May 8, 2023, Apyx Medical Corporation (the “Company”) closed the previously announced sale and leaseback of its facility located at 5115 Ulmerton Road, Clearwater, Florida, with VK Acquisitions VI, LLC for a purchase price of $7,650,000. Following the closing, the Company received net cash proceeds of approximately $6,600,000 after withholding the security deposit equal to one years rent, taxes, first months rent, expenses and fees.
33

Table of Contents
APYX MEDICAL CORPORATION
ITEM 6. Exhibits

3.1 |  | Articles of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant’s report on Form 10-K/A filed on March 31, 2011)
3.2 |  | By laws of the Registrant (Incorporated by reference to Exhibit 3.2 to the Registrant’s report on Form 10-K/A filed on March 31, 2011)
3.3 |  | Certificate of Amendment of the Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.5 to the Registrant’s Quarterly Report on Form 10-Q filed on November 3, 2017)
3.4 |  | Certificate of Elimination (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on May 3, 2018)
3.5 |  | Certificate of Amendment of the Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on December 28, 2018)
31.1* |  | Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002
31.2* |  | Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002
32.1* |  | Certification pursuant to Section 906 of Sarbanes-Oxley Act of 2002
32.2* |  | Certification pursuant to Section 906 of Sarbanes-Oxley Act of 2002
101.INS** |  | XBRL Instance Document
101.SCH** |  | XBRL Taxonomy Extension Schema Document
101.CAL** |  | XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF** |  | XBRL Taxonomy Extension Definition Linkbase Document
101.LAB** |  | XBRL Taxonomy Extension Label Linkbase Document
101.PRE** |  | XBRL Taxonomy Extension Label Presentation Document

* Filed herewith.
** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended and otherwise is not subject to liability under these sections.
34

Table of Contents
APYX MEDICAL CORPORATION
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| Apyx Medical Corporation |
Date: May 11, 2023 | By: | /s/ Charles D. Goodwin II |
|  | Charles D. Goodwin II |
|  | President, Chief Executive Officer and Director |
|  | (Principal Executive Officer) |
Date: May 11, 2023 | By: | /s/ Tara Semb |
|  | Tara Semb |
|  | Chief Financial Officer, |
|  | Treasurer and Secretary |
|  | (Principal Financial Officer) |

35